FreshWebTR 8
Biopharma
Gero
The single-partner-concentration bear point is dead — Gero now has TWO pharma validations, and the bigger one (Chugai/Roche, exclusive worldwide antibody rights, up to ~$250M milestones + royalties) is disclosed on a listed Roche subsidiary's own corporate filing, the most credible source in this dossier. Plus an open-sourced sequence-to-molecule model (ProtoBind-Diff). Still WATCHING (private, no public security, no named owned IND asset), but the watch is materially higher-quality — conviction on the platform-validation leg rises from "one partner, unfalsifiable" to "two top-tier pharma partners + a verifiable open-source artifact." The asymmetric event is now a partner advancing a target to the clinic or an institutional/crossover up-round.
View profile